Biopharma In China: The Emerging Global Force Of Domestic Suppliers

By Vicky Xia and Leo Yang

Quite a few Chinese biopharma companies are shifting their purchase of supplies from global multinational corporation (MNC) vendors to domestic vendors for their clinical stage projects via process changes. Many say domestic substitution would be more common if the National Medical Products Administration (NMPA) gets more lenient with process changes.